AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 171 min read$GLUE

Warmuth Markus sold $220K of GLUE

Warmuth Markus (President & CEO) sold 9,500 shares of Monte Rosa Therapeutics, Inc. (GLUE) at $23.18 ($0.22M total) on 2026-07-16.

Original reporting
SEC EDGAR · Warmuth Markus
Published Jul 17, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 17, 2026, 8:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$GLUE
Neutral
medium confidence
Mentioned
$GLUE
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GLUENeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale details (shares, price, total value) and that it was not under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone does not change the company’s fundamentals.

03

What to watch

The article does not state whether the CEO has other holdings, prior sale patterns, or tax-related reasons; absence of a 10b5-1 plan does not prove intent.

Relevance 4/10Novelty 3/10Timing: after-hours filing timestamp on 2026-07-17 for a sale dated 2026-07-16

Background

The article is an SEC Form 4 insider transaction disclosure for Monte Rosa Therapeutics, Inc. (GLUE).

Company-level read

Ticker impact

$GLUENeutralMedium confidence
Context

SEC Form 4 shows GLUE CEO Warmuth sold 9,500 shares on 2026-07-16 for about $220.2K at $23.1809.

Expected impact

Likely limited near-term price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing discloses transaction size, price, and absence of a pre-arranged 10b5-1 plan, but provides no new company-specific operating or financial information.

Market effects

Sector

No clear sector read-through from a single CEO sale filing.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be for diversification or liquidity needs and does not necessarily signal reduced confidence in the business.

Key entities

  • issuer
    GLUE

    Monte Rosa Therapeutics, Inc., the company whose CEO filed the Form 4 insider sale.

  • insider
    Warmuth Markus

    President and CEO who sold 9,500 shares on 2026-07-16.

Read at source← All news

Related articles

AUG 6
$GLUEMed

Monte Rosa Therapeutics reports Q2 2026 net loss $43.4M, cash position $626.0M supporting operations into 2029

Monte Rosa Therapeutics reported a Q2 2026 net loss of $43.4M, with collaboration revenue of $9.0M. Cash, cash equivalents, restricted cash, and marketable securities totaled $626.0M as of June 30, 2026, supporting operations into 2029. R&D and G&A rose year over year. The company advanced MRT-8102 and other programs, including Novartis-activated MRT-6160 Phase 2.

tradingview.com1 min
AUG 6
$GLUEMed

Monte Rosa Therapeutics, Inc. (GLUE): Results of Operations and Financial Condition

Monte Rosa Therapeutics, Inc. (GLUE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 glue-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk; readout

SEC EDGAR 8-K6 min
JUL 31
$GLUEMed

Why is Monte Rosa Therapeutics stock plunging today?

Amazon shares rally as cloud growth surges and spending outlook climbs Investing.com -- Monte Rosa Therapeutics shares plummeted nearly 29.9% in pre-open trading today, trading at $15.90, after Novo Nordisk disclosed that its Phase 3 ZEUS cardiovascular outcomes trial for ziltivekimab — an IL-6 pathway inhibitor — failed to demonstrate a statistically meaningful reduction in major adverse cardiovascular events versus placebo in patients with atherosclerotic cardiovascular disease, chronic...

investing.com4 min
JUN 5
$GLUEMedAI 9/10

Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy

Monte Rosa Therapeutics (GLUE) reported May 7 progress in its clinical pipeline, with three programs moving toward Phase 2. MRT-8102 (NEK7) showed CRP reductions in early trials and plans multiple Phase 2 starts in H2 2026. MRT-6160 (VAV1) with Novartis and MRT-2359 (GSPT1) in mCRPC also advance, with a Phase 2 combo with apalutamide planned for Q3 2026. The company reported $671M cash, expected to fund operations into 2029.

finance.yahoo.com4 min
MAY 29
$GLUEMedAI 9/10

Molecule glue drugs shake up cancer care, draw big money

Revolution Medicines (RevMed) said its daraxonrasib doubled survival in aggressive pancreatic cancer, from 6.7 to 13.2 months, with final-stage results due at a Chicago medical conference. The outcome has spurred dealmaking and development of “molecular glue” drugs targeting “undruggable” proteins. RevMed’s market cap neared $33B; it plans FDA filing and an ultrafast review, with projected $7B annual sales by 2032.

economictimes.indiatimes.com6 min